How to verify a compounding pharmacy or 503B outsourcing facility

Verify a compounder by exact legal name and physical address in the applicable state pharmacy record and, when the seller claims section 503B status, in FDA’s current Registered Outsourcing Facilities table. Then match the dispensed or administered product to that facility through the label, lot, date, prescription or office-stock route, shipping record, inspection history, and recall record. Neither a state license nor 503B registration means FDA approved the finished compounded drug.¹³

This is a record-matching job, not a logo check. One company can operate multiple facilities, use a trade name, move, change permits, or have one address registered under 503B while another is not.

Start with the product in hand

Before searching a database, copy the label exactly:

• patient name, if present;
• drug name, strength, dosage form, route, and volume;
• compounder’s legal name, trade name, address, and phone;
• prescription or order identifier;
• lot or batch number;
• beyond-use date;
• storage conditions; and
• prescriber, dispenser, or clinic record connecting the product to the patient.

A clinic invoice that says only “peptide,” “B12 blend,” “GLP-1,” or “wellness IV” cannot be reconciled to a finished product. Ask for the ingredients and concentrations rather than inferring them from the menu.

State and federal records answer different questions

FDA’s current 503B table is address-specific and updated weekly. It explains that registration must be renewed annually, that newly registered facilities may not yet have been inspected, and that a Form 483 contains inspection observations rather than a final agency determination.¹

Use 503A and 503B only after matching the facility

Section 503A generally describes qualifying compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, under conditions that include a patient-specific prescription framework. Section 503B creates an outsourcing-facility category that may distribute qualifying compounded drugs without patient-specific prescriptions, including office stock, and is subject to current good manufacturing practice requirements and FDA risk-based inspection.³⁴

Those are conditional statutory pathways, not product approvals. Compounded drugs are not FDA approved, so FDA does not premarket-verify their safety, effectiveness, or manufacturing quality as it does for approved drugs.³

The practical question is not “Is 503B better?” It is “Which pathway does this exact transaction claim, and does the source, product, order, and distribution record fit it?”

Match names, addresses, and dates literally

Search variations of the legal and trade name, but resolve the result to one physical facility. Compare suite number, city, state, and ZIP. A corporate headquarters, mail address, pharmacy address, and manufacturing address may differ.

Record:

1. database name and search date;
2. legal facility name;
3. physical address;
4. permit or registration type;
5. current status and expiration or registration date;
6. last inspection shown;
7. whether a Form 483, warning letter, recall, or other action is linked; and
8. the product label fields that connect the facility to the dose.

For a Florida pharmacy, identify the permit type from the Florida Board of Pharmacy licensing categories and verify the entity in the state health-provider search.⁵ An active permit is one layer; the product and federal record remain separate.

Read an inspection timeline without flattening it

FDA’s compounding actions page groups documents by facility and address.² Read each document’s type and date:

• a Form 483 lists investigators’ observations at inspection close;
• a facility response is the firm’s account of corrective action;
• a warning letter states FDA’s position on described violations at that time;
• a closeout letter addresses the warning-letter response, not every future operation;
• a recall has product, lot, distribution, and reason boundaries; and
• an “open” action field means FDA has not yet determined whether further action will occur.

The FDA public-action guide prevents a recall from being confused with a warning letter or an inspection observation.

The lot is the bridge between a facility and a patient

Facility status cannot answer whether a particular vial was made there, remained within storage conditions, was recalled, or was administered as labeled. Preserve a clear photograph of every label face and packaging, plus the invoice, order, shipping temperature record when applicable, clinic receipt log, preparation record, and administration record.

If a clinic will not disclose the source or lot before administration, the consumer cannot complete the most basic recall and product-identity check.

Registration is not an endorsement

FDA explicitly distinguishes oversight from approval. The agency does not approve outsourcing facilities simply because they register, and registration does not show that every listed product qualifies for section 503B exemptions.¹ State licensure likewise does not prove a finished compound is FDA approved.

Avoid claims such as “FDA-certified pharmacy,” “FDA-approved facility,” or “pharmaceutical grade” unless the speaker provides the exact authoritative record and explains what it covers. The approval-status guide decodes similar language.

Verify the chain, then decide what remains unknown

1. Capture the finished-product identity. Photograph the complete label and record drug, formulation, route, lot, dates, storage, and named compounder.
2. Resolve one legal facility. Match trade and legal names to a physical address rather than a corporate logo or marketplace profile.
3. Check the state record. Verify permit category, current status, address, dates, and posted discipline in the applicable board system.
4. Test the 503B claim. If office stock or outsourcing status is claimed, match the same facility to FDA's current registration table and its registration period.
5. Read inspections and recalls by document. Separate observations, responses, warning letters, closeouts, recalls, and open actions without converting any one into a universal verdict.
6. Connect the lot to administration. Preserve ordering, receipt, storage, preparation, administrator, and patient-record evidence so the facility record actually applies to the dose.

The decisive question is: “Can this exact compounded dose be traced, by legal facility, address, pathway, formulation, lot, and date, through current state and FDA records all the way to my treatment record?”